I have neuropathic pain. I’ve tried 3 brands now, this last one being less expensive. I “think” it’s helping a little bit…. maybe it’s wishful thinking. I never really knew how much to take. There is so much confusion on dosing, so I just take a dropper full now. Maybe that’s too much, maybe not. Should I take it twice a day, or once? I find it very hard to compare brand to brand. Thank you for your detailed, informative article. If anyone would care to share how much oil they take daily, I would appreciate it. I’m just trying to get a rough idea of what’s normal, an average. thanks.
Some CBD manufacturers have come under government scrutiny for wild, indefensible claims, such that CBD is a cure-all for cancer, which it is not. We need more research but CBD may be prove to be an option for managing anxiety, insomnia, and chronic pain. Without sufficient high-quality evidence in human studies we can’t pinpoint effective doses, and because CBD is currently is mostly available as an unregulated supplement, it’s difficult to know exactly what you are getting. If you decide to try CBD, talk with your doctor — if for no other reason than to make sure it won’t affect other medications you are taking.
Disclaimer: The entire contents of this website are based upon the opinions of Dr. Mercola, unless otherwise noted. Individual articles are based upon the opinions of the respective author, who retains copyright as marked. The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Mercola and his community. Dr. Mercola encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. If you are pregnant, nursing, taking medication, or have a medical condition, consult your health care professional before using products based on this content.
“We would strongly warn against using a vaporizer to vape CBD hemp oil products because we haven’t seen one yet that doesn’t contain thinning agents that can be very toxic,” Lee said. “Thinning agents like propylene glycol and polyethylene glycol should not be in a product that you’re going to eat or inhale. Flavoring agents that are added to CBD hemp products should be a red flag. I think they should be avoided because the FDA hasn’t approved any of these flavoring agents for being heated and inhaled.”
Cannabinoids are a class of compounds that interact with receptors throughout your body. CBD is just one of dozens of cannabinoids found in cannabis, including tetrahydrocannabinol (THC), which is the one responsible for marijuana’s famous high. Medical cannabis is technically any cannabis product used for medicinal purposes, and these can contain THC or CBD or both, said Nick Jikomes, a neuroscientist at Leafly, a website that provides information about legal cannabis. “A common mistake people make is to think that CBD is ‘the medical cannabinoid’ and THC is ‘the recreational cannabinoid.’” That’s inaccurate, he said, because THC is a potent anti-inflammatory and can be helpful for pain.
Soil characteristics, latitude and climatic stresses have been found to have significant effects on THC concentrations, and there are seasonal and even diurnal variations (Small 1979; Pate 1998b). However, the range of THC concentrations developed by low-THC cultivars (those typically with £0.3% THC) under different circumstances on the whole is limited, for the most part generally not varying more than 0.2 percentage points when grown in a range of circumstances, and usually less (note information in Scheifle et al. 1999; Scheifle 2000, Scheifle and Dragla 2000). Practically, this has meant in Canadian experience that a few cultivars have been eliminated from further commercial cultivation because they sometimes exceed the 0.3% level (‘Fedora 19’ and ‘Futura,’ authorized in 2000, have now been removed because some test results in several years exceeded 0.3%; ‘Finola’ and ‘Uniko B’ are under probation because of elevated levels), but on the whole most of the permitted cultivars have maintained highly consistent development of quite low levels of THC.
Hemp paper is high-priced for several reasons. Economies of scale are such that the supply of hemp is minute compared to the supply of wood fiber. Hemp processing requires non-wood-based processing facilities. Hemp paper is typically made only from bast fibers, which require separation from the hurds, thereby increasing costs. This represents less than 50% of the possible fiber yield of the plant, and future technologies that pulp the whole stalks could decrease costs substantially. Hemp is harvested once a year, so that it needs to be stored to feed mills throughout the year. Hemp stalks are very bulky, requiring much handling and storage. Transportation costs are also very much higher for hemp stalks than for wood chips. Waste straw is widely available from cereals and other crops, and although generally not nearly as desirable as hemp, can produce bulk pulp far more cheaply than can be made from hemp. In addition to agricultural wastes, there are vast quantities of scrub trees, especially poplar, in northern areas, that can supply large amounts of low-quality wood fiber extremely cheaply. Moreover, in northern areas fast-growing poplars and willows can be grown, and such agro-forestry can be very productive and environmentally benign. And, directly or indirectly, the lumber/paper industry receives subsidies and/or supports, which is most unlikely for hemp.
In Japan, hemp was historically used as paper and a fiber crop. There is archaeological evidence cannabis was used for clothing and the seeds were eaten in Japan back to the Jōmon period (10,000 to 300 BC). Many Kimono designs portray hemp, or asa (Japanese: 麻), as a beautiful plant. In 1948, marijuana was restricted as a narcotic drug. The ban on marijuana imposed by the United States authorities was alien to Japanese culture, as the drug had never been widely used in Japan before. Though these laws against marijuana are some of the world's strictest, allowing five years imprisonment for possession of the drug, they exempt hemp growers, whose crop is used to make robes for Buddhist monks and loincloths for Sumo wrestlers. Because marijuana use in Japan has doubled in the past decade, these exemptions have recently been called into question.
"Both hemp and marijuana also have separate definitions in statute. While marijuana is defined in U.S. drug laws, Congress established a statutory definition for industrial hemp as “the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis” as part of the 2014 farm bill.4 Hemp is generally characterized by plants that are low in delta-9 tetrahydrocannabinol (delta-9 THC), the dominant psychotrophic ingredient in Cannabis sativa.5
Cannabis plants produce a unique family of terpeno-phenolic compounds called cannabinoids, some of which produce the "high" which may be experienced from consuming marijuana. There are 483 identifiable chemical constituents known to exist in the cannabis plant, and at least 85 different cannabinoids have been isolated from the plant. The two cannabinoids usually produced in greatest abundance are cannabidiol (CBD) and/or Δ9-tetrahydrocannabinol (THC), but only THC is psychoactive. Since the early 1970s, Cannabis plants have been categorized by their chemical phenotype or "chemotype", based on the overall amount of THC produced, and on the ratio of THC to CBD. Although overall cannabinoid production is influenced by environmental factors, the THC/CBD ratio is genetically determined and remains fixed throughout the life of a plant. Non-drug plants produce relatively low levels of THC and high levels of CBD, while drug plants produce high levels of THC and low levels of CBD. When plants of these two chemotypes cross-pollinate, the plants in the first filial (F1) generation have an intermediate chemotype and produce intermedite amounts of CBD and THC. Female plants of this chemotype may produce enough THC to be utilized for drug production.
People are turning to CBD oil to treat their pain more and more. Whether acute to chronic, pain can be located in different areas of the body and may be experienced at different intensities. This wide range of pain complaints among individual may call for different types of treatment that are more comprehensive than just swallowing a general prescription pill. The good news is that CBD can be applied topically or consumed orally. Furthermore, CBD can be taken sublingually, smoked, eaten, or even vaporized, depending on the product. In this way, CBD can treat pain very specifically rather than generally, because let’s face it, one size does not fit all.
Executives from Canopy Growth CGC, -1.22% WEED, -1.27% and rival Aurora Cannabis Inc. ACB, -0.88% ACB, -0.83% both discussed their hemp operations on September-quarter earnings calls that included disappointing results related to early recreational pot sales. Aurora declined to comment on the latest developments and Canopy did not make executives available by the time of publication.
While CBD is considered the major non-psychoactive component of cannabis, in studies using varied doses, routes of administration, and combination or whole products with THC, a number of side effects have been reported, including anxiety, changes in appetite and mood, diarrhea, dizziness, drowsiness, dry mouth, low blood pressure, mental confusion, nausea, and vomiting.
In some areas where cannabis use had been historically tolerated, new restrictions were instituted, such as the closing of cannabis coffee shops near the borders of the Netherlands, and closing of coffee shops near secondary schools in the Netherlands. In Copenhagen, Denmark in 2014, mayor Frank Jensen discussed possibilities for the city to legalize cannabis production and commerce.
Since the late 1970s, the federal Healthy People Initiative has been a visible component of the United States’ approach to improving population health. In each decade, a new version of Healthy People is issued, featuring updated goals and identifying topic areas and quantifiable objectives for health improvement during the succeeding ten years, with assessment at that point of progress or lack thereof. Progress has been limited to many objectives, leading to concerns about the effectiveness of Healthy People in shaping outcomes in the context of a decentralized and uncoordinated US health system. Healthy People 2020 gives more prominence to health promotion and preventive approaches and adds a substantive focus on the importance of addressing social determinants of health. A new expanded digital interface facilitates use and dissemination rather than bulky printed books as produced in the past. The impact of these changes to Healthy People will be determined in the coming years.
Dosage is important, because CBD can have side effects—the most common are tiredness, diarrhea, and changes in appetite and weight—so it’s best not to take more than you need. As CBD becomes more prevalent, says J. Michael Bostwick, M.D., a psychiatrist at Mayo Clinic in Rochester, MN, “I’m reasonably certain new kinds of side effects will emerge.”
Receptra offers their products in two separate lines. One is the Active Lifestyle range, which provides lower concentrations for daily use, and another is Health and Wellness, which is for far more intense use. It is incredibly difficult for me to manage my back pain with a low concentration of CBD usually, so, I went with the 3000 mg concentration available in their Health and Wellness line.
Both in Canada and the US, the most critical problem to be addressed for commercial exploitation of C. sativa is the possible unauthorized drug use of the plant. Indeed, the reason hemp cultivation was made illegal in North America was concern that the hemp crop was a drug menace. The drug potential is, for practical purposes, measured by the presence of THC. THC is the world’s most popular illicit chemical, and indeed the fourth most popular recreational drug, after caffeine, alcohol, and nicotine. “Industrial hemp” is a phrase that has become common to designate hemp used for commercial non-intoxicant purposes. Small and Cronquist (1976) split C. sativa into two subspecies: C. sativa subsp. sativa, with less than 0.3% (dry weight) of THC in the upper (reproductive) part of the plant, and C. sativa subsp. indica (Lam.) E. Small & Cronq. with more than 0.3% THC. This classification has since been adopted in the European Community, Canada, and parts of Australia as a dividing line between cultivars that can be legally cultivated under license and forms that are considered to have too high a drug potential. For a period, 0.3% was also the allowable THC content limit for cultivation of hemp in the Soviet Union. In the US, Drug Enforcement Agency guidelines issued Dec. 7, 1999 expressly allowed products with a THC content of less than 0.3% to enter the US without a license; but subsequently permissible levels have been a source of continuing contention. Marijuana in the illicit market typically has a THC content of 5% to 10% (levels as high as 25% have been reported), and as a point of interest, a current Canadian government experimental medicinal marijuana production contract calls for the production of 6% marijuana. As noted above, a level of about 1% THC is considered the threshold for marijuana to have intoxicating potential, so the 0.3% level is conservative, and some countries (e.g. parts of Australia, Switzerland) have permitted the cultivation of cultivars with higher levels. It should be appreciated that there is considerable variation in THC content in different parts of the plant. THC content increases in the following order: achenes (excluding bracts), roots, large stems, smaller stems, older and larger leaves, younger and smaller leaves, flowers, perigonal bracts covering both the female flowers and fruits. It is well known in the illicit trade how to screen off the more potent fractions of the plant in order to increase THC levels in resultant drug products. Nevertheless, a level of 0.3% THC in the flowering parts of the plant is reflective of material that is too low in intoxicant potential to actually be used practically for illicit production of marijuana or other types of cannabis drugs. Below, the problem of permissible levels of THC in food products made from hempseed is discussed.
The first of Berenson’s questions concerns what has long been the most worrisome point about cannabis: its association with mental illness. Many people with serious psychiatric illness smoke lots of pot. The marijuana lobby typically responds to this fact by saying that pot-smoking is a response to mental illness, not the cause of it—that people with psychiatric issues use marijuana to self-medicate. That is only partly true. In some cases, heavy cannabis use does seem to cause mental illness. As the National Academy panel declared, in one of its few unequivocal conclusions, “Cannabis use is likely to increase the risk of developing schizophrenia and other psychoses; the higher the use, the greater the risk.”